Article
MRI/MRSI is best suited for patients with newly diagnosed prostate cancer who are at high risk of extracapsular extent and who are considering various forms of local therapy.
Enrollment goal met in phase 3 SOLAR-RECUR trial
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
FDA accepts sNDA for darolutamide plus ADT in mHSPC
Key updates from the AUA/ASRM male infertility guideline amendment
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
Dean Laganosky, M.D., named Urology Trailblazer for 2024